Renunda Hicks

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

A Monoclonal Antibody for Malaria Prevention.

J. Mascola, Zonghui Hu, A. McDermott, 2021, The New England journal of medicine.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

J. Mascola, R. Koup, C. Andrews, 2019, The Lancet.

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

J. Mascola, D. Baltimore, E. Boritz, 2022, Nature Medicine.

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

J. Mascola, R. Koup, J. Casazza, 2022, Nature Medicine.

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Carmen M. Graves, J. Mascola, R. Koup, 2023, Science Translational Medicine.